D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 133 Citations 76,605 533 World Ranking 71 National Ranking 51
Medicine D-index 137 Citations 81,215 630 World Ranking 770 National Ranking 470

Research.com Recognitions

Awards & Achievements

Member of the Association of American Physicians

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Asthma
  • Disease

His main research concerns Asthma, Immunology, Internal medicine, Placebo and Allergy. His biological study spans a wide range of topics, including Anesthesia, Exacerbation, Randomized controlled trial, Intensive care and Physical therapy. His study in Immunology is interdisciplinary in nature, drawing from both Bronchoalveolar lavage and Airway.

His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Omalizumab. His Placebo research also works with subjects such as

  • Surgery which intersects with area such as Rheumatoid arthritis,
  • Clinical endpoint that connect with fields like Lebrikizumab. His Allergy research is multidisciplinary, relying on both Family medicine and Immunopathology.

His most cited work include:

  • Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) (3245 citations)
  • Asthma. From bronchoconstriction to airways inflammation and remodeling. (1529 citations)
  • Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program (1383 citations)

What are the main themes of his work throughout his whole career to date?

His scientific interests lie mostly in Asthma, Immunology, Internal medicine, Placebo and Eosinophil. William W. Busse studies Fluticasone propionate which is a part of Asthma. His work on Immunology is being expanded to include thematically relevant topics such as Airway.

His Internal medicine study combines topics in areas such as Gastroenterology, Omalizumab and Endocrinology. His Eosinophil research is multidisciplinary, incorporating elements of Molecular biology and Bronchoalveolar lavage. His research integrates issues of Dry-powder inhaler and Bronchodilator in his study of Anesthesia.

He most often published in these fields:

  • Asthma (54.53%)
  • Immunology (44.00%)
  • Internal medicine (25.86%)

What were the highlights of his more recent work (between 2014-2021)?

  • Asthma (54.53%)
  • Internal medicine (25.86%)
  • Immunology (44.00%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Asthma, Internal medicine, Immunology, Omalizumab and Placebo. His work carried out in the field of Asthma brings together such families of science as Exacerbation, Immunoglobulin E and Intensive care medicine. His work on Adverse effect, Severe asthma and Corticosteroid as part of general Internal medicine research is often related to In patient, thus linking different fields of science.

His studies deal with areas such as Gene expression and Airway as well as Immunology. The various areas that William W. Busse examines in his Omalizumab study include Clinical effectiveness, Observational study, Allergic asthma and Asthma exacerbations. His research in Placebo intersects with topics in Randomized controlled trial, Randomization, Intention-to-treat analysis, Rate ratio and COPD.

Between 2014 and 2021, his most popular works were:

  • Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial (564 citations)
  • Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma (501 citations)
  • Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. (283 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Asthma
  • Disease

The scientist’s investigation covers issues in Asthma, Immunology, Internal medicine, Intensive care medicine and Omalizumab. His Asthma research includes themes of Exacerbation, Adverse effect and Disease. His Immunology study combines topics from a wide range of disciplines, such as Differentially methylated regions and DNA methylation.

William W. Busse interconnects Gastroenterology and Placebo in the investigation of issues within Internal medicine. The Placebo study combines topics in areas such as Rate ratio, Anesthesia and Randomized controlled trial. His Intensive care medicine research incorporates elements of Inhaled corticosteroids, β2 agonists, Maintenance therapy and Allergy.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs

J. Bousquet;H. J. Schünemann;B. Samolinski;P. Demoly.
The Journal of Allergy and Clinical Immunology (2012)

7730 Citations

Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)

J. Bousquet;N. Khaltaev;A. A. Cruz;J. Denburg.
Allergy (2008)

5823 Citations

Asthma. From bronchoconstriction to airways inflammation and remodeling.

Jean Bousquet;Peter K. Jeffery;William W. Busse;Malcolm Johnson.
American Journal of Respiratory and Critical Care Medicine (2000)

2578 Citations

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.

Eric D. Bateman;Homer A. Boushey;Jean Bousquet;William W. Busse.
American Journal of Respiratory and Critical Care Medicine (2004)

2181 Citations

Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program

Wendy C. Moore;Deborah A. Meyers;Sally E. Wenzel;W. Gerald Teague.
american thoracic society international conference (2010)

2024 Citations

An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice.

Helen K. Reddel;D. Robin Taylor;Eric D. Bateman;Louis-Philippe Boulet.
American Journal of Respiratory and Critical Care Medicine (2009)

1251 Citations

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

William Busse;Jonathan Corren;Bobby Quentin Lanier;Margaret McAlary.
The Journal of Allergy and Clinical Immunology (2001)

1149 Citations

Efficacy and safety of inhaled corticosteroids. New developments.

Peter J. Barnes;Søren Pedersen;William W. Busse.
American Journal of Respiratory and Critical Care Medicine (1998)

1098 Citations

Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial

Romain A Pauwels;Søren Pedersen;William W Busse;Wan C Tan.
The Lancet (2003)

950 Citations

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

J Mark FitzGerald;Eugene R Bleecker;Parameswaran Nair;Stephanie Korn.
The Lancet (2016)

883 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing William W. Busse

Jean Bousquet

Jean Bousquet

Inserm : Institut national de la santé et de la recherche médicale

Publications: 286

Claus Bachert

Claus Bachert

Ghent University

Publications: 231

Giorgio Walter Canonica

Giorgio Walter Canonica

Humanitas University

Publications: 213

Pascal Demoly

Pascal Demoly

University of Montpellier

Publications: 186

Stanley J. Szefler

Stanley J. Szefler

University of Colorado Denver

Publications: 183

Sally E. Wenzel

Sally E. Wenzel

University of Pittsburgh

Publications: 180

Nikolaos G. Papadopoulos

Nikolaos G. Papadopoulos

University of Manchester

Publications: 179

Sebastian L. Johnston

Sebastian L. Johnston

National Institutes of Health

Publications: 178

Peter G. Gibson

Peter G. Gibson

University of Newcastle Australia

Publications: 176

David Price

David Price

University of Aberdeen

Publications: 173

Peter J. Barnes

Peter J. Barnes

Imperial College London

Publications: 152

Kian Fan Chung

Kian Fan Chung

National Institutes of Health

Publications: 150

Paul M. O'Byrne

Paul M. O'Byrne

McMaster University

Publications: 148

Ian D. Pavord

Ian D. Pavord

University of Oxford

Publications: 148

James E. Gern

James E. Gern

University of Wisconsin–Madison

Publications: 143

Christopher E. Brightling

Christopher E. Brightling

University of Leicester

Publications: 142

Trending Scientists

Arnold Tukker

Arnold Tukker

Leiden University

Jerome Pasquero

Jerome Pasquero

Blackberry (United States)

Yuichiro Himeda

Yuichiro Himeda

National Institute of Advanced Industrial Science and Technology

Alex B. F. Martinson

Alex B. F. Martinson

Argonne National Laboratory

Tsutomu Ogata

Tsutomu Ogata

Hamamatsu University

Sue McIntyre

Sue McIntyre

Commonwealth Scientific and Industrial Research Organisation

Bernd Blossey

Bernd Blossey

Cornell University

Welington Luiz Araújo

Welington Luiz Araújo

Universidade de São Paulo

Thomas P. Sakmar

Thomas P. Sakmar

Rockefeller University

Lev G. Goldfarb

Lev G. Goldfarb

National Institutes of Health

Sussan Nourshargh

Sussan Nourshargh

Queen Mary University of London

Domingo Barber

Domingo Barber

CEU San Pablo University

Christoph Mundt

Christoph Mundt

Heidelberg University

Bernard Weiner

Bernard Weiner

University of California, Los Angeles

Knut Borch-Johnsen

Knut Borch-Johnsen

Aarhus University

Seth G. Jones

Seth G. Jones

Center for Strategic and International Studies

Something went wrong. Please try again later.